RegeneRx Biopharmaceuticals (United States)
Clinical results in patients with NK treated with RGN-259 have previously demonstrated efficacy in a small number of patients (18) in the first phase 3 clinical trial (SEER-1). Based on these results, two independent clinical trials are underway designed to confirm SEER-1 and significantly shorten the clinical development period (SEER-2 and SEER-3). The double-masked, placebo-controlled trials will be conducted by administering RGN-259 or placebo eye drops for four weeks to approximately 70 NK p
Basic Information
- Category: business
- Website: http://www.regenerx.com/
Documented Facts
- Email: info@regenerx.com (No linked source recorded for this statement.)
Evidence and Sources
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about RegeneRx Biopharmaceuticals (United States).
- Canonical profile: https://brandsource.ai/brands/regenerx-biopharmaceuticals-united-states
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/regenerx-biopharmaceuticals-united-states/json-ld
- Citation profile API: https://brandsource.ai/api/brands/regenerx-biopharmaceuticals-united-states/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (77/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-21
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Clinical results in patients with NK treated with RGN-259 have previously demonstrated efficacy in a small number of patients (18) in the first phase 3 clinical trial (SEER-1). Based on these results, two independent clinical trials are underway designed to confirm SEER-1 and significantly shorten the clinical development period (SEER-2 and SEER-3). The double-masked, placebo-controlled trials will be conducted by administering RGN-259 or placebo eye drops for four weeks to approximately 70 NK p
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 1 structured fact available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.